Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





TB-Related Articles										Related Pages
										Return to Main Menu**2020 DTBE Publications**
Agizew T, Boyd R, Mathebula U, Mathoma A, Basotli J, Serumola C, Pals S, Finlay A, Lekone P, Rankgoane-Pono G, Tlhakanelo T, Chihota V, Auld AF. Outcomes of HIV-positive patients with non-tuberculous mycobacteria positive culture who received anti-tuberculous treatment in Botswana: Implications of using diagnostic algorithms without non-tuberculous mycobacteria.external icon PLoS One. 2020 Jun 12;15(6):e0234646. doi: 10.1371/journal.pone.0234646. eCollection 2020. PMID: 32530972.
Agizew T, Surie D, Oeltmann JE, Letebele M, Pals S, Mathebula U, Mathoma A, Kassa M, Hamda S, Pono P, Rankgoane-Pono G, Boyd R, Auld A, Finlay A. Tuberculosis preventive treatment opportunities at antiretroviral therapy initiation and follow-up visits.external icon Public Health Action. 2020 Jun 21;10(2):64-69. doi: 10.5588/pha.19.0056. PMID: 32639479.Year202120202019201820172016201520142013Ahmed A, Feng PI, Gaensbauer JT, Reves RR, Khurana R, Salcedo K, Punnoose R, Katz DJ; Tuberculosis Epidemiologic Studies Consortium. Interferon-γ Release Assays in Children <15 Years of Age.external icon Pediatrics. 2020 Jan;145(1):e20191930. doi: 10.1542/peds.2019-1930. PMID: 31892518.
Armstrong LR, Kammerer JS, Haddad MB. Diabetes mellitus among adults with tuberculosis in the USA, 2010-2017.external icon BMJ Open Diabetes Res Care. 2020 Jul;8(1). pii: e001275. doi: 10.1136/bmjdrc-2020-001275. PMID: 32641300.
Auld AF, Agizew T, Mathoma A, Boyd R, Date A, Pals SL, Serumola C, Mathebula U, Alexander H, Ellerbrock TV, Rankgoane-Pono G, Pono P, Shepherd JC, Fielding K, Grant AD, Finlay A. Effect of tuberculosis screening and retention interventions on early antiretroviral therapy mortality in Botswana: a stepped-wedge cluster randomized trial.external icon BMC Med. 2020 Feb 11;18(1):19. doi: 10.1186/s12916-019-1489-0. PMID: 32041583.
Auld AF, Fielding K, Agizew T, Maida A, Mathoma A, Boyd R, Date A, Pals SL, Bicego G, Liu Y, Shiraishi RW, Ehrenkranz P, Serumola C, Mathebula U, Alexander H, Charalambous S, Emerson C, Rankgoane-Pono G, Pono P, Finlay A, Shepherd JC, Holmes C, Ellerbrock TV, Grant AD. Risk scores for predicting early antiretroviral therapy mortality in sub-Saharan Africa to inform who needs intensification of care: a derivation and external validation cohort study. external iconBMC Med. 2020 Nov 9;18(1):311. doi: 10.1186/s12916-020-01775-8. PMID: 33161899.
Beeler Asay GR, Lam CK, Stewart B, Mangan JM, Romo L, Marks SM, Baepubmrah Morris S, Gummo CL, Keh CE, Hill AN, Thomas A, Macaraig M, St John K, J Ampie T, Chuck C, Burzynski J. Cost of tuberculosis therapy directly observed on video for health departments and patients in New York City; San Francisco, California; and Rhode Island (2017–2018)external icon. Am J Public Health. 2020 Nov;110(11):1696-1703. doi: 10.2105/AJPH.2020.305877. Epub 2020 Sep 17. PMID: 32941064.
Bisson GP, Bastos M, Campbell JR, Bang D, Brust JC, Isaakadis P, Lange C, Menzies D, Migliori GB, Pape JW, Palmero D, Baghei P, Tabarsi P, Viiklepp P, Vilbrun S, Walsh J, Marks SM. Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. external iconLancet. 2020 Aug 8;396(10248):402-411. doi: 10.1016/S0140-6736(20)31316-7. PMID: 32771107.
Bonney W, Price SF; PMP1, Abhyankar S, Merrick R, Hampole V, Halse TA, DiDonato C, Dalton T, Metchock B, Starks AM, Miramontes R. Towards Unified Data Exchange Formats for Reporting Molecular Drug Susceptibility Testing. external icon Online J Public Health Inform. 2020 Dec 8;12(2):e14. doi: 10.5210/ojphi.v12i2.10644. eCollection 2020. PMID: 33381280.
Cegielski JP, Chan PC, Lan Z, Udwadia ZF, Viiklepp P, Yim JJ, Menzies D. Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009-2016.external icon Clin Infect Dis. 2020 Oct 30:ciaa621. doi: 10.1093/cid/ciaa621. [Epub ahead of print]. PMID: 33124668.
Cegielski JP, Udwadia ZF, Viiklepp P, Yim JJ, Menzies D. Reply to van Deun and Decroo. external icon
Clin Infect Dis. 2020 Dec 20:ciaa1875. doi: 10.1093/cid/ciaa1875. [Epub ahead of print].
PMID: 33341886.
Chen MP, Miramontes R, Kammerer JS. Multidrug-resistant tuberculosis in the United States, 2011-2016: patient characteristics and risk factors.external icon Int J Tuberc Lung Dis. 2020 Jan 1;24(1):92-99. doi: 10.5588/ijtld.19.0173. PMID: 32005311.
Chorba T, Jereb J. Confusion in the Genesis of Art and Disease: Charles Laval, Paul Gauguin, and Tuberculosisexternal icon. Emerg Infect Dis. 2020 Mar; 26(3):634–635. doi: 10.3201/eid2603.AC2603.
Click ES, Finlay A, Oeltmann JE, Basotli J, Modongo C, Boyd R, Wen XJ, Shepard J, Moonan PK, Zetola N. Phylogenetic diversity of Mycobacterium tuberculosis in two geographically distinct locations in Botswana – The Kopanyo Study.external icon Infect Genet Evol. 2020 Jul;81:104232. doi: 10.1016/j.meegid.2020.104232. Epub 2020 Feb 3. PMID: 32028055.
Click ES, Kurbatova E, Alexander H, Dalton TL, Chen MP, Posey JE, Ershova JJ, Cegielski P. Isoniazid- and Rifampin-Resistance Mutations Associated with Resistance to Second-line Drugs and with Sputum Culture Conversion.external icon J Infect Dis. 2020 Jun 11;221(12):2072-2082. doi: 10.1093/infdis/jiaa042. PMID: 32002554.
Cole B, Nilsen DM, Will L, Etkind SC, Burgos M, Chorba T. Essential Components of a Public Health Tuberculosis Prevention, Control, and Elimination Program: Recommendations of the Advisory Council for the Elimination of Tuberculosis and the National Tuberculosis Controllers Association. MMWR Recomm Rep. 2020 Jul 31; 69(7): 1–27. doi: 10.15585/mmwr.rr6907a1. PMID: 32730235.
Collins JM, Stout JE, Ayers T, Hill AN, Katz DJ, Ho CS, Blumberg HM, Winglee K. Tuberculosis Epidemiologic Studies Consortium.Prevalence of latent tuberculosis infection among non-U.S.-born persons by country of birth—United States, 2012–2017external icon. Clin Infect Dis. 2020 Nov 2. pii: 5952274. doi: 10.1093/cid/ciaa1662. [Epub ahead of print]. PMID:  33137172.
Cronin AM, Railey S, Fortune D, Hope Wegener D, Davis JB. Notes from the Field: Effects of the COVID-19Response on Tuberculosis Prevention and Control Efforts – United States, March-April 2020. MMWR Morb Mortal Wkly Rep. 2020 Jul 24; 69(29):971–972. doi: 10.15585/mmwr.mm6929a4. PMID: 32701944.
DeGruy K, Klein K, Rey Z, Hall P, Kim A, Alexander H. Development of dried tube specimens for Xpert MTB/RIF proficiency testing.external icon Afr J Lab Med. 2020 Sep 29;9(1):1166. doi: 10.4102/ajlm.v9i1.1166. eCollection 2020. PMID: 33102169.
de Perio MA, Kobayashi M, Wortham JM. Occupational Respiratory Infections. external iconClin Chest Med. 2020 Dec;41(4):739-751. doi: 10.1016/j.ccm.2020.08.003. PMID: 33153691.
Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, Johnson JL, Lessem E, Metchock B, Miro JM, Nhung NV, Pettit AC, Phillips PPJ, Podany AT, Purfield AE, Robergeau K, Samaneka W, Scott NA, Sizemore E, Vernon A, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group and the Tuberculosis Trials Consortium. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.external icon Contemp Clin Trials. 2020 Mar; 90:105938. doi: 10.1016/j.cct.2020.105938. Epub 2020 Jan 22. PMID: 31981713.
Ershova JV, Volchenkov GV, Somova TR, Kuznetsova TA, Kaunetis NV, Kaminski D, Demikhova OV, Chernousova LN, Vasilyeva IA, Kerr EM, Cegielski JP, Kurbatova EV. Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia. external icon BMC Infect Dis. 2020 Jul 25;20(1):543. doi: 10.1186/s12879-020-05243-9.
PMID: 32711457.
Fernando R, McDowell AC, Bhavaraju R, Fraimow H, Wilson JW, Armitige L, Haley C, Goswami ND. A model for bringing TB expertise to HIV providers: Medical consultations to the CDC-funded Regional Tuberculosis Training and Medical Consultation Centers, 2013-2017. external iconPLoS One. 2020 Aug 31;15(8):e0236933. doi: 10.1371/journal.pone.0236933. eCollection 2020. PMID: 32866154.
Figueroa A, Vonnahme L, Burrell K, Vera-García C, Gulati RK. CureTB and continuity of care for globally mobile patients. external iconInt J Tuberc Lung Dis. 2020 Jul 1;24(7):694-699. doi: 10.5588/ijtld.19.0486. PMID: 32718402.
Gobaud AN, Haley CA, Wilson JW, Bhavaraju R, Lardizabal A, Seaworth BJ, Goswami ND. Multidrug-resistant tuberculosis care in the United States.external icon Int J Tuberc Lung Dis. 2020 Apr 1;24(4):409-413. doi: 10.5588/ijtld.19.0515. PMID: 32317065.
Haddad MB, Lash TL, Castro KG, Hill AN, Navin TR, Gandhi NR, Magee MJ. Tuberculosis Infection Among People With Diabetes: United States Population Differences by Race/Ethnicity.external icon Am J Prev Med. 2020 Jun;58(6):858-863. doi: 10.1016/j.amepre.2019.12.010. Epub 2020 Feb 13. PMID: 32061457.
Haley CA, Macias P, Jasuja S, Jones BA, Rowlinson MC, Jaimon R, Onderko P, Darnall E, Gomez ME, Peloquin C, Ashkin D, Goswami ND. Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States.external icon Emerg Infect Dis. 2021 Jan;27(1):332-334. doi: 10.3201/eid2701.203766. Epub 2020 Nov 23. PMID: 33227229.
Hill AN, Cohen T, Salomon JA, Menzies NA. High-resolution estimates of tuberculosis incidence among non-U.S.-born persons residing in the United States, 2000-2016.external icon Epidemics. 2020 Nov 10;33:100419. doi: 10.1016/j.epidem.2020.100419. [Epub ahead of print]. PMID: 33242759.
Iqbal SA, Isenhour CJ, Mazurek G, Truman BI. Diagnostic code agreement for electronic health records and claims data for tuberculosis. external iconInt J Tuberc Lung Dis. 2020 Jul 1;24(7):706-711. doi: 10.5588/ijtld.19.0792. PMID: 32718404.
Jo Y, Shrestha S, Gomes I, Marks S, Hill A, Asay G, Dowdy D. Model-Based Cost-Effectiveness of State-level Latent Tuberculosis Interventions in California, Florida, New York and Texas.external icon Clin Infect Dis. 2020 Jun 25. pii: ciaa857. doi: 10.1093/cid/ciaa857. [Epub ahead of print]. PMID: 32584968.
Kerr EM, Vonnahme LA, Goswami ND. Impact of Targeted Local Interventions on Tuberculosis Awareness and Screening Among Persons Experiencing Homelessness During a Large Tuberculosis Outbreak in Atlanta, Georgia, 2015-2016. external icon Public Health Rep. 2020. Jul/Aug;135(1_suppl):90S-99S. doi: 10.1177/0033354920932644. PMID: 32735200.
Klein K, DeGruy K, Rey Z, Hall P, Kim A, Gutreuter S, Alexander H.  A global proficiency testing programme for Xpert® MTB/RIF using dried tube specimens, 2013-2015. external iconAfr J Lab Med. 2020 Nov 27;9(1):1167. doi: 10.4102/ajlm.v9i1.1167. eCollection 2020. PMID: 33354528.
Klopper M, Heupink TH, Hill-Cawthorne G, Streicher EM, Dippenaar A, de Vos M, Abdallah AM, Limberis J, Merker M, Burns S, Niemann S, Dheda K, Posey J, Pain A, Warren RM. A landscape of genomic alterations at the root of a near-untreatable tuberculosis epidemic.external icon BMC Med. 2020 Feb 4;18(1):24. doi: 10.1186/s12916-019-1487-2. PMID: 32014024.
Lienhardt C, Nunn A, Chaisson R, Vernon AA, Zignol M, Nahid P, Delaporte E, Kasaeva T. Advances in clinical trial design: Weaving tomorrow’s TB treatments.external icon PLoS Med. 2020 Feb 27;17(2):e1003059. doi: 10.1371/journal.pmed.1003059. eCollection 2020 Feb. PMID: 32106220.
Liu Y, Phares CR, Posey DL, Maloney SA, Cain KP, Weinberg MS, Schmit KM, Marano N, Cetron MS. Tuberculosis among Newly Arrived Immigrants and Refugees in the United States. external iconAnn Am Thorac Soc. 2020 Jul 30. doi: 10.1513/AnnalsATS.201908-623OC. [Epub ahead of print]. PMID: 32730094.
Marks SM, Dowdy DW, Menzies NA, Shete PB, Salomon JA, Parriott A, Shrestha S, Flood J, Hill AN. Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination.external icon Public Health Rep. 2020 Jul/Aug;135(1_suppl):38S-43S. doi: 10.1177/0033354920912710. PMID: 32735183.
Marks SM, Katz DJ, Davidow AL, Pagaoa MA, Teeter LD, Graviss EA. The Impact of HIV Infection on TB Disparities Among US-Born Black and White Tuberculosis Patients in the United States. external icon J Public Health Manag Pract. 2020 Sep/Oct;26(5):E5-E12. doi: 10.1097/PHH.0000000000000949. PMID: 32732731.
Mathebula U, Emerson C, Agizew T, Pals S, Boyd R, Mathoma A, Basotli J, Rankgoane-Pono G, Serumola C, Date A, Auld AF, Finlay A. Improving sputum collection processes to increase tuberculosis case finding among HIV-positive persons in Botswana.external icon Public Health Action. 2020 Mar 21;10(1):11-16. doi: 10.5588/pha.19.0051. PMID: 32368518.
McDowell A, Haas M, Seaworth B, Wilson JW, Patrawalla A, Haley C, Lauzardo M, de Bruyn M, Goswami ND. Linezolid use for the treatment of multidrug-resistant tuberculosis, TB centers of excellence, United States, 2013-2018. external iconJ Clin Tuberc Other Mycobact Dis. 2020 Nov 16;22:100201. doi: 10.1016/j.jctube.2020.100201. eCollection 2021 Feb. PMID: 33336084.
Mehaffy C, Kruh-Garcia NA, Graham B, Jarlsberg LG, Willyerd CE, Borisov A, Sterling TR, Nahid P, Dobos KM. Identification of *Mycobacterium tuberculosis* peptides in serum extracellular vesicles from persons with latent tuberculosis infection.external icon J Clin Microbiol. 2020 May 26;58(6):e00393-20. doi: 10.1128/JCM.00393-20. PMID: 32245831.
Menzies NA, Bellerose M, Testa C, Swartwood N, Malyuta Y, Cohen T, Marks SM, Hill AN, Date AA, Maloney SA, Bowden SE, Grills AW, Salomon JA. Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States.external icon Am J Respir Crit Care Med. 2020 Jul 9. doi: 10.1164/rccm.202003-0526OC. [Epub ahead of print]. PMID: 32645277.
Menzies NA, Swartwood N, Testa C, Malyuta Y, Hill AN, Marks SM, Cohen T, Salomon, JA. Time Since Infection and Risks of Future Disease for Individuals with *Mycobacterium tuberculosis* Infection in the United Statesexternal icon. Epidemiology. 2021 Jan; 32(1): 70–78. Epub 2020 Sep 29. doi: 10.1097/EDE.0000000000001271. PMID: 33009253.
Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in Pregnancy.external icon Obstet Gynecol. 2020 Jun;135(6):1444-1453. doi: 10.1097/AOG.0000000000003890. PMID: 32459437.
Muloma E, Stewart R, Townsend H, Koch S, Burkholder S, Railey S, White K, Redington-Noble R, Caine V. Multipronged Approach to Controlling a Tuberculosis Outbreak Among Persons Experiencing Homelessness. external icon J Public Health Manag Pract. 2020 Sep 9. doi: 10.1097/PHH.0000000000001211. [Epub ahead of print]. PMID: 32956287.
Nabity SA, Mponda K, Gutreuter S, Surie D, Williams A, Sharma AJ, Schnaubelt ER, Marshall RE, Kirking HL, Zimba SB, Sunguti JL, Chisuwo L, Chiwaula MJ, Gregory JF, da Silva R, Odo J, Jahn A, Kalua T, Nyirenda R, Girma B, Buono N, Maida A, Kim EJ, Gunde LJ, Mekonnen TK, Auld AF, Muula AS, Oeltmann JE. Protocol for a Case-Control Study to Investigate the Association of Pellagra With Isoniazid Exposure During Tuberculosis Preventive Treatment Scale-Up in Malawiexternal icon. Front Public Health. 2020 Nov 26; 8:551308. doi: 10.3389/fpubh.2020.551308. eCollection 2020. PMID: 33324593.
Punetha A, Ngo HX, Holbrook SYL, Green KD, Willby MJ, Bonnett SA, Krieger K, Dennis EK, Posey JE, Parish T, Tsodikov OV, Garneau-Tsodikova S. Structure-Guided Optimization of Inhibitors of Acetyltransferase Eis from *Mycobacterium tuberculosis.*external icon ACS Chem Biol. 2020 Jun 19;15(6):1581-1594.  doi: 10.1021/acschembio.0c00184.  Epub 2020 May 18. PMID: 32421305.
Reichler MR, Hirsch C, Yuan Y, Khan A, Dorman SE, Schluger N, Sterling TR; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Predictive value of TNF-α, IFN-γ, and IL-10 for tuberculosis among recently exposed contacts in the United States and Canada. external icon BMC Infect Dis. 2020 Jul 31;20(1):553. doi: 10.1186/s12879-020-05185-2. PMID: 32736606.
Reichler MR, Khan A, Yuan Y, Chen B, McAuley J, Mangura B, Sterling TR; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Duration of Exposure Among Close Contacts of Patients With Infectious Tuberculosis and Risk of Latent Tuberculosis Infection.external icon Clin Infect Dis. 2020 Feb 11;ciz1044. doi: 10.1093/cid/ciz1044. [Epub ahead of print]. PMID: 32044987.
Rossetti A.  Latent TB Infection: New Guidelines and Preferred Treatments.external icon Medscape 2020.
Schmit KM, Shah N, Kammerer S, Bamrah Morris S, Marks SM. Tuberculosis Transmission or Mortality Among Persons Living with HIV, USA, 2011-2016.external icon J Racial Ethn Health Disparities. 2020 Feb 14. doi: 10.1007/s40615-020-00709-7. [Epub ahead of print]. PMID: 32060748.
Schmit KM, Wortham JM, Ho CS, Powell KM. Analysis of severe adverse events reported among patients receiving isoniazid-rifapentine treatment for latent Mycobacterium tuberculosis infection – United States, 2012-2016.external icon Clin Infect Dis. 2020 Mar 18;ciaa286. doi: 10.1093/cid/ciaa286. [Epub ahead of print]. PMID: 32185390.
Schwartz NG, Price SF, Pratt RH, Langer AJ. Tuberculosis – United States, 2019.external icon MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):286-289. doi: 10.15585/mmwr.mm6911a3. PMID: 32191684.
Shrestha S, Parriott A, Menzies NA, Shete PB, Hill AN, Marks SM, Dowdy DW. Estimated Population-level Impact of Using a Six-Week Regimen of Daily Rifapentine to Treat Latent Tuberculosis Infection in the United States. external iconAnn Am Thorac Soc. 2020 Sep 11. doi: 10.1513/AnnalsATS.202005-574RL. [Epub ahead of print]. PMID: 32916062.
Sotgiu G, Battista Migliori G, Menzies D, Mase S, Chorba T, Seaworth B, Nahid P. Reply to: “ATS/CDC/ERS/IDSA Clinical Practice Guidelines for Treatment of Drug-resistant TB: A Two-edged Sword?”.external icon Am J Respir Crit Care Med Actions. 2020 May 6. doi: 10.1164/rccm.202003-0698LE. [Epub ahead of print]. PMID: 32374628.
Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR Jr, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. external icon MMWR Recomm Rep. 2020 Feb 14;69(1):1-11. doi: 10.15585/mmwr.rr6901a1. PMID: 32053584.
Stewart RJ, Wortham J, Parvez F, Morris SB, Kirking HL, Cameron LH, Cruz AT. Tuberculosis Infection in Childrenexternal icon. J Nurse Pract. 2020 Oct; 16(9):673-678. doi: 10.1016/j.nurpra.2020.06.027.
Talwar A, Stewart R, Althomsons SP, Rinsky J, Jackson DA, Galvis ME, Graham P, Huaman MA, Karrer J, Kondapally K, Mitchell S, Wortham J, de Fijter S. *Notes from the Field:* Multidrug-Resistant Tuberculosis Among Workers at Two Food Processing Facilities — Ohio, 2018–2019external icon. MMWR Morb Mortal Wkly Rep. 2020 Aug 14; 69(32): 1104–1105. Published online 2020 Aug 14. doi: 10.15585/mmwr.mm6932a6. PMID: 32790660.
Tsang CA, Langer AJ, Kammerer JS, Navin TR. US Tuberculosis Rates among Persons Born Outside the United States Compared with Rates in Their Countries of Birth, 2012-20161. external iconEmerg Infect Dis. 2020 Mar;26(3):533-540. doi: 10.3201/eid2603.190974.Emerg Infect Dis. 2020. PMID: 32091367.
Wang EY, Arrazola RA, Mathema B, Ahluwalia IB, Mase SR. The impact of smoking on tuberculosis treatment outcomes: a meta-analysis.external icon Int J Tuberc Lung Dis. 2020 Feb 1;24(2):170-175. doi: 10.5588/ijtld.19.0002. PMID: 32127100.
Warria K, Nyamthimba P, Chweya A, Agaya J, Achola M, Reichler M, Cowden J, Heilig CM, Borgdorff MW, Cain KP, Yuen C. Tuberculosis disease and infection among household contacts of bacteriologically confirmed and non-confirmed tuberculosis patients.external icon Trop Med Int Health. 2020 Jun;25(6):695-701. doi: 10.1111/tmi.13392. Epub 2020 Apr 6. PMID: 32170771.
Weiner M, Gelfond J, Johnson-Pais TL, Engle M, Johnson JL, Whitworth WC, Bliven-Sizemore E, Nsubuga P, Dorman SE, Savic R; Pharmacokinetics/Pharmacodynamics Group of Tuberculosis Trials Consortium. Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis. external iconJ Antimicrob Chemother. 2020 Dec 29:dkaa490. doi: 10.1093/jac/dkaa490. [Epub ahead of print]. PMID: 33374006.
Willby M, Chopra P, Lemmer D, Klein K, Dalton TL, Engelthaler DM, Cegielski P, Posey JE; Global PETTS Investigators. Molecular evaluation of fluoroquinolone resistance in serial Mycobacterium tuberculosis isolates from individuals diagnosed with multidrug-resistant tuberculosisexternal icon. Antimicrob Agents Chemother. 2020 Oct 26:AAC.01663-20. doi: 10.1128/AAC.01663-20. [Epub ahead of print]. PMID: 33106264.
Yelk Woodruff R, Hill A, Marks S, Navin T, Miramontes R. Estimated Latent Tuberculosis Infection Prevalence and Tuberculosis Reactivation Rates Among Non-U.S.-Born Residents in the United States, from the 2011-2012 National Health and Nutrition Examination Survey. external iconJ Immigr Minor Health. 2020 Aug 5. doi: 10.1007/s10903-020-01065-8. [Epub ahead of print]. PMID: 32761297.

*Last updated March 26, 2021*
							
					
						Page last reviewed:  April 8, 2021										Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue